MEDICINOVA INC
MNOVNASDAQ🏆 #3219 by market capUS Equity
$403.38▲ $23.84 (+5.91%)
Simulated price1h—
24h▲ 5.9%
7d—
14d—
30d—
1y—
🏦Market Cap
$71M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
8.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
118.0x
Expensive
Otter Score
61
Fair
No chart data available for MNOV.
Trading Snapshot
- Day Range
- $400.77 – $410.97
- 52-Week Range
- $1.17 – $1.96
- Volume
- $1.63B
- Avg Volume
- $1.75B
- Shares Outstanding
- 49.2M
- Next Earnings
- Sep 24, 2026
Fundamentals Snapshot
- Annual Revenue
- $602,898
- Last Q Revenue
- $139,437
- P/E Ratio
- —
- P/S Ratio
- 118.0x
- EPS (TTM)
- $-0.24
- Dividend Yield
- —
Why Investors Own MNOV
- ✓High-growth profile — revenue up +51.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$602,898▲ +57.3% YoY
Gross Margin (TTM)
45.1%▲ +4.5% YoY
Operating Income (TTM)
$223,675▲ +57.3% YoY
Free Cash Flow (TTM)
$173,032▲ +57.3% YoY
About MEDICINOVA INC
A company profile for MEDICINOVA INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
61/100
Analyst Price Target
ⓘAverage Target
$433.52
▲ +7.5% Upside
High Target$479.24
Low Target$342.27
Based on 38 analysts
Latest News & Updates
🚀
Barron’s·2h ago
MEDICINOVA INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift MNOV price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
MEDICINOVA INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.